These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 20957635)

  • 1. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
    Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
    Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
    van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
    J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
    van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
    Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
    J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and preclinical investigation of
    Shah SQ; Gul-E-Raana
    Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
    Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
    Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
    Terry SY; Abiraj K; Lok J; Gerrits D; Franssen GM; Oyen WJ; Boerman OC
    J Nucl Med; 2014 Nov; 55(11):1849-55. PubMed ID: 25349221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.
    Terry SY; Abiraj K; Frielink C; van Dijk LK; Bussink J; Oyen WJ; Boerman OC
    J Nucl Med; 2014 Feb; 55(2):281-6. PubMed ID: 24408894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
    Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
    J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse.
    Skvortsova I; Skvortsov S; Raju U; Stasyk T; Riesterer O; Schottdorf EM; Popper BA; Schiestl B; Eichberger P; Debbage P; Neher A; Bonn GK; Huber LA; Milas L; Lukas P
    Radiother Oncol; 2010 Jul; 96(1):108-15. PubMed ID: 20451273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
    Gong JH; Liu XJ; Li Y; Zhen YS
    Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
    van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
    Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
    Koi L; Bergmann R; Brüchner K; Pietzsch J; Pietzsch HJ; Krause M; Steinbach J; Zips D; Baumann M
    Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
    Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
    PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib.
    Bozec A; Formento P; Fischel JL; Etienne-Grimaldi MC; Milano G
    Oral Oncol; 2010 Mar; 46(3):172-7. PubMed ID: 20156700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.